{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:25:53Z","timestamp":1783081553290,"version":"3.54.6"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00105-026-05722-1","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:43:12Z","timestamp":1781613792000},"page":"433-440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemischer Pruritus: h\u00e4matologische, nephrogene und hepatobili\u00e4re Ursachen im Fokus","Systemic pruritus: focus on hematological, nephrogenic, and hepatobiliary etiologies"],"prefix":"10.1007","volume":"77","author":[{"given":"Steffen","family":"Koschmieder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas E.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"5722_CR1","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2147\/JBM.S319441","volume":"12","author":"M Abu-Tineh","year":"2021","unstructured":"Abu-Tineh\u00a0M, Aljaloudi\u00a0E, Yassin\u00a0MA (2021) Pruritus as a\u00a0Presenting Symptom of FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia. J\u00a0Blood Med 12:1061\u20131063","journal-title":"J Blood Med"},{"key":"5722_CR2","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.revmed.2003.12.015","volume":"25","author":"Y Afifi","year":"2004","unstructured":"Afifi\u00a0Y, Aubin\u00a0F, Puzenat\u00a0E et\u00a0al (2004) Pruritus sine materia: a prospective study of 95 patients. Rev Med Interne 25:490\u2013493","journal-title":"Rev Med Interne"},{"key":"5722_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clinre.2018.07.010","volume":"43","author":"A Baker","year":"2019","unstructured":"Baker\u00a0A, Kerkar\u00a0N, Todorova\u00a0L et\u00a0al (2019) Systematic review of progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol 43:20\u201336","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"5722_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41575-022-00687-7","volume":"20","author":"U Beuers","year":"2023","unstructured":"Beuers\u00a0U, Wolters\u00a0F, Oude Elferink\u00a0RPJ (2023) Mechanisms of pruritus in cholestasis: understanding and treating the itch. Nat Rev Gastroenterol Hepatol 20:26\u201336","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5722_CR5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20243dw20248ey20245h","author":"J Burton","year":"2024","unstructured":"Burton\u00a0J, Perrin\u00a0A, Ruessmann\u00a0D (2024) Prevalence and Burden of CKD-Associated Pruritus in Europe (CENSUS-EU): FR-PO1144. Journal of the American Society of Nephrology. https:\/\/doi.org\/10.1681\/ASN.20243dw20248ey20245h","journal-title":"Journal of the American Society of Nephrology"},{"key":"5722_CR6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","volume":"160","author":"E De Vries","year":"2021","unstructured":"De Vries\u00a0E, Bolier\u00a0R, Goet\u00a0J et\u00a0al (2021) Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial. Gastroenterology 160:734\u2013743","journal-title":"Gastroenterology"},{"key":"5722_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/10781552231221149","volume":"31","author":"G Dranitsaris","year":"2025","unstructured":"Dranitsaris\u00a0G, Neuhalfen\u00a0H, Peevyhouse\u00a0A et\u00a0al (2025) Diagnosis and management of systemic mastocytosis in a community hematology setting. J\u00a0Oncol Pharm Pract 31:31\u201338","journal-title":"J Oncol Pharm Pract"},{"key":"5722_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.cld.2022.06.009","volume":"26","author":"MM Dull","year":"2022","unstructured":"Dull\u00a0MM, Kremer\u00a0AE (2022) Evaluation and Management of Pruritus in Primary Biliary Cholangitis. Clin Liver Dis 26:727\u2013745","journal-title":"Clin Liver Dis"},{"key":"5722_CR9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","volume":"77","author":"European Association for the Study of The L","year":"2022","unstructured":"European Association for the Study of The L (2022) EASL Clinical Practice Guidelines on sclerosing cholangitis. J\u00a0Hepatol 77:761\u2013806","journal-title":"J Hepatol"},{"key":"5722_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/ijd.14708","volume":"59","author":"KMV Eusebio-Alpapara","year":"2020","unstructured":"Eusebio-Alpapara\u00a0KMV, Castillo\u00a0RL, Dofitas\u00a0BL (2020) Gabapentin for uremic pruritus: a\u00a0systematic review of randomized controlled trials. Int J Dermatol 59:412\u2013422","journal-title":"Int J Dermatol"},{"key":"5722_CR11","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jaad.2013.11.045","volume":"70","author":"N Fett","year":"2014","unstructured":"Fett\u00a0N, Haynes\u00a0K, Propert\u00a0KJ et\u00a0al (2014) Five-year malignancy incidence in patients with chronic pruritus: a population-based cohort study aimed at limiting unnecessary screening practices. J\u00a0Am Acad Dermatol 70:651\u2013658","journal-title":"J Am Acad Dermatol"},{"key":"5722_CR12","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","volume":"398","author":"E Gonzales","year":"2021","unstructured":"Gonzales\u00a0E, Hardikar\u00a0W, Stormon\u00a0M et\u00a0al (2021) Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet 398:1581\u20131592","journal-title":"Lancet"},{"key":"5722_CR13","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1097\/HEP.0000000000000727","volume":"79","author":"BE Hansen","year":"2024","unstructured":"Hansen\u00a0BE, Vandriel\u00a0SM, Vig\u00a0P et\u00a0al (2024) Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA. Hepatology 79:1279\u20131292","journal-title":"Hepatology"},{"key":"5722_CR14","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","volume":"96","author":"CN Harrison","year":"2017","unstructured":"Harrison\u00a0CN, Koschmieder\u00a0S, Foltz\u00a0L et\u00a0al (2017) The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol 96:1653\u20131665","journal-title":"Ann Hematol"},{"key":"5722_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2468-1253(25)00192-X","volume":"11","author":"GM Hirschfield","year":"2026","unstructured":"Hirschfield\u00a0GM, Bowlus\u00a0CL, Jones\u00a0DEJ et\u00a0al (2026) Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 11:22\u201333","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5722_CR16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield\u00a0GM, Bowlus\u00a0CL, Mayo\u00a0MJ et\u00a0al (2024) A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N\u00a0Engl J Med 390:783\u2013794","journal-title":"N Engl J Med"},{"key":"5722_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01407-y","volume":"24","author":"M Hu","year":"2024","unstructured":"Hu\u00a0M, Scheffel\u00a0J, Frischbutter\u00a0S et\u00a0al (2024) Characterization of cells and mediators associated with pruritus in primary cutaneous T\u2011cell lymphomas. Clin Exp Med 24:171","journal-title":"Clin Exp Med"},{"key":"5722_CR18","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1681\/ASN.2018010096","volume":"29","author":"JH Ishida","year":"2018","unstructured":"Ishida\u00a0JH, Mcculloch\u00a0CE, Steinman\u00a0MA et\u00a0al (2018) Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients. J\u00a0Am Soc Nephrol 29:1970\u20131978","journal-title":"J Am Soc Nephrol"},{"key":"5722_CR19","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/ijd.14562","volume":"58","author":"A Khokar","year":"2019","unstructured":"Khokar\u00a0A, Malik\u00a0U, Butt\u00a0G et\u00a0al (2019) Cutaneous manifestations in chronic myeloid leukemia in chronic phase treated with imatinib. Int J Dermatol 58:1098\u20131101","journal-title":"Int J Dermatol"},{"key":"5722_CR20","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKDWG","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes CKDWG (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105:S117\u2013S314","journal-title":"Kidney Int"},{"key":"5722_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley\u00a0KV, Bowlus\u00a0CL, Levy\u00a0C et\u00a0al (2024) Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N\u00a0Engl J Med 390:795\u2013805","journal-title":"N Engl J Med"},{"key":"5722_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/HEP.0000000000000728","volume":"80","author":"AE Kremer","year":"2024","unstructured":"Kremer\u00a0AE, Mayo\u00a0MJ, Hirschfield\u00a0GM et\u00a0al (2024) Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology 80:27\u201337","journal-title":"Hepatology"},{"key":"5722_CR23","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jaad.2018.08.044","volume":"80","author":"VA Larson","year":"2019","unstructured":"Larson\u00a0VA, Tang\u00a0O, Stander\u00a0S et\u00a0al (2019) Association between itch and cancer in 16,925 patients with pruritus: Experience at a tertiary care center. J\u00a0Am Acad Dermatol 80:931\u2013937","journal-title":"J Am Acad Dermatol"},{"key":"5722_CR24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/jdv.18990","volume":"37","author":"C Le Gall-Ianotto","year":"2023","unstructured":"Le Gall-Ianotto\u00a0C, Ficheux\u00a0AS, Lippert\u00a0E et\u00a0al (2023) Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients. J\u00a0Eur Acad Dermatol Venereol 37:1175\u20131183","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5722_CR25","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1111\/jth.14588","volume":"17","author":"P Le Gall-Ianotto","year":"2019","unstructured":"Le Gall-Ianotto\u00a0P, Le Calloch\u00a0R, Couturier\u00a0MA et\u00a0al (2019) Aquagenic pruritus in essential thrombocythemia is associated with a higher risk of thrombosis. J\u00a0Thromb Haemost 17:1950\u20131955","journal-title":"J Thromb Haemost"},{"key":"5722_CR26","doi-asserted-by":"crossref","unstructured":"Levy C, Jones DEJ, Mayo MJ et\u00a0al. (2026) Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase\u00a03 RESPONSE Trial. Aliment Pharmacol Ther","DOI":"10.1111\/apt.70630"},{"key":"5722_CR27","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41375-025-02524-7","volume":"39","author":"K Manz","year":"2025","unstructured":"Manz\u00a0K, Heidel\u00a0FH, Koschmieder\u00a0S et\u00a0al (2025) Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN). Leukemia 39:864\u2013875","journal-title":"Leukemia"},{"key":"5722_CR28","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","volume":"68","author":"MJ Mayo","year":"2023","unstructured":"Mayo\u00a0MJ, Carey\u00a0E, Smith\u00a0HT et\u00a0al (2023) Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis. Dig Dis Sci 68:995\u20131005","journal-title":"Dig Dis Sci"},{"key":"5722_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/jorc.70017","volume":"51","author":"K Mccafferty","year":"2025","unstructured":"Mccafferty\u00a0K, Schaufler\u00a0T, Molina\u00a0P et\u00a0al (2025) Influence of Baseline Itch Severity on Treatment Outcomes With Difelikefalin in Adults With Moderate-to-Severe Pruritus Receiving Maintenance Haemodialysis: An Exploratory Analysis. J\u00a0Ren Care 51:e70017","journal-title":"J Ren Care"},{"key":"5722_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/23247096241255840","volume":"12","author":"BJ Mccormick","year":"2024","unstructured":"Mccormick\u00a0BJ, Zieman\u00a0D, Sluzevich\u00a0JC et\u00a0al (2024) Clinical Features of Cutaneous Paraneoplastic Syndromes in Hodgkin Lymphoma. J\u00a0Investig Med High Impact Case Rep 12:23247096241255840","journal-title":"J Investig Med High Impact Case Rep"},{"key":"5722_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjh.14382","volume":"176","author":"R Mesa","year":"2017","unstructured":"Mesa\u00a0R, Vannucchi\u00a0AM, Yacoub\u00a0A et\u00a0al (2017) The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol 176:76\u201385","journal-title":"Br J Haematol"},{"key":"5722_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000553","volume":"5","author":"RA Mesa","year":"2021","unstructured":"Mesa\u00a0RA, Schaap\u00a0N, Vannucchi\u00a0AM et\u00a0al (2021) Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. Hemasphere 5:e553","journal-title":"Hemasphere"},{"key":"5722_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2340\/00015555-0789","volume":"90","author":"N Meyer","year":"2010","unstructured":"Meyer\u00a0N, Paul\u00a0C, Misery\u00a0L (2010) Pruritus in cutaneous T\u2011cell lymphomas: frequent, often severe and difficult to treat. Acta Derm Venereol 90:12\u201317","journal-title":"Acta Derm Venereol"},{"key":"5722_CR34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S2468-1253(24)00080-3","volume":"9","author":"AG Miethke","year":"2024","unstructured":"Miethke\u00a0AG, Moukarzel\u00a0A, Porta\u00a0G et\u00a0al (2024) Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 9:620\u2013631","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5722_CR35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens\u00a0F, Andreone\u00a0P, Mazzella\u00a0G et\u00a0al (2016) A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N\u00a0Engl J Med 375:631\u2013643","journal-title":"N Engl J Med"},{"key":"5722_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/bjc.1973.10","volume":"27","author":"KA Newton","year":"1973","unstructured":"Newton\u00a0KA, Mackenzie\u00a0DH, Spittle\u00a0MF et\u00a0al (1973) Hodgkin\u2019s disease. A clinico-pathological study of 250 cases with a 5\u2011year follow-up. Br J Cancer 27:80\u201391","journal-title":"Br J Cancer"},{"key":"5722_CR37","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.abd.2021.06.007","volume":"97","author":"TR Nietsche","year":"2022","unstructured":"Nietsche\u00a0TR, Dotta\u00a0G, Barcaui\u00a0CB et\u00a0al (2022) Cholestatic pruritus: a knowledge update. An Bras Dermatol 97:332\u2013337","journal-title":"An Bras Dermatol"},{"key":"5722_CR38","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S2468-1253(24)00074-8","volume":"9","author":"N Ovchinsky","year":"2024","unstructured":"Ovchinsky\u00a0N, Aumar\u00a0M, Baker\u00a0A et\u00a0al (2024) Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol 9:632\u2013645","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5722_CR39","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.jaip.2022.02.018","volume":"10","author":"S Radonjic-Hoesli","year":"2022","unstructured":"Radonjic-Hoesli\u00a0S, Martignoni\u00a0Z, Cazzaniga\u00a0S et\u00a0al (2022) Characteristics of Dermatological Patients With Blood Eosinophilia: A Retrospective Analysis of 453 Patients. J\u00a0Allergy Clin Immunol Pract 10:1229\u20131237","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5722_CR40","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.2215\/CJN.03280317","volume":"12","author":"HC Rayner","year":"2017","unstructured":"Rayner\u00a0HC, Larkina\u00a0M, Wang\u00a0M et\u00a0al (2017) International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis. Clin J Am Soc Nephrol 12:2000\u20132007","journal-title":"Clin J Am Soc Nephrol"},{"key":"5722_CR41","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3630","volume":"100","author":"M Robert","year":"2020","unstructured":"Robert\u00a0M, Misery\u00a0L, Brenaut\u00a0E (2020) Chronic Pruritus in the Absence of Skin Disease: A\u00a0Retrospective Study of 197 French Inpatients. Acta Derm Venereol 100:adv00274","journal-title":"Acta Derm Venereol"},{"key":"5722_CR42","doi-asserted-by":"crossref","unstructured":"Royeck S, Olbrich H, Koschmieder S et\u00a0al. (2026) Elevated lymphoma risk in patients with chronic pruritus and chronic prurigo. J\u00a0Dtsch Dermatol Ges","DOI":"10.1111\/ddg.70057"},{"key":"5722_CR43","doi-asserted-by":"publisher","first-page":"705","DOI":"10.4103\/ijd.ijd_326_21","volume":"66","author":"S Saini","year":"2021","unstructured":"Saini\u00a0S, Jain\u00a0AK, Agarwal\u00a0S et\u00a0al (2021) Iron Deficiency and Pruritus: A Cross-Sectional Analysis to Assess Its Association and Relationship. Indian J Dermatol 66:705","journal-title":"Indian J Dermatol"},{"key":"5722_CR44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1684\/ejd.2019.3560","volume":"29","author":"K Shimizu","year":"2019","unstructured":"Shimizu\u00a0K, Andoh\u00a0T, Makino\u00a0T et\u00a0al (2019) Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression. Eur J Dermatol 29:268\u2013273","journal-title":"Eur J Dermatol"},{"key":"5722_CR45","unstructured":"Siebenhaar F, Broesby-Olsen S, Castells M et\u00a0al. (2026) Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase\u00a02, interventional PIONEER study. J\u00a0Am Acad Dermatol"},{"key":"5722_CR46","unstructured":"Smith HT, Das S, Fettiplace J et\u00a0al. (2025) Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study. Hepatol Commun\u00a09"},{"key":"5722_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18125","volume":"28","author":"B Solak","year":"2024","unstructured":"Solak\u00a0B, Kara\u00a0RO (2024) Systemic inflammation and its relationship with pruritus in early-stage mycosis fungoides. J\u00a0Cell Mol Med 28:e18125","journal-title":"J Cell Mol Med"},{"key":"5722_CR48","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/ddg.14830","volume":"20","author":"S Stander","year":"2022","unstructured":"Stander\u00a0S, Zeidler\u00a0C, Augustin\u00a0M et\u00a0al (2022) S2k guideline: Diagnosis and treatment of chronic pruritus. J\u00a0Dtsch Dermatol Ges 20:1387\u20131402","journal-title":"J Dtsch Dermatol Ges"},{"key":"5722_CR49","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/ddg.14830_g","volume":"20","author":"S Stander","year":"2022","unstructured":"Stander\u00a0S, Zeidler\u00a0C, Augustin\u00a0M et\u00a0al (2022) S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus. J\u00a0Dtsch Dermatol Ges 20:1386\u20131402","journal-title":"J Dtsch Dermatol Ges"},{"key":"5722_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101448","volume":"7","author":"F Terracciani","year":"2025","unstructured":"Terracciani\u00a0F, De Vincentis\u00a0A, D\u2019amato\u00a0D et\u00a0al (2025) Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world. JHEP Rep 7:101448","journal-title":"JHEP Rep"},{"key":"5722_CR51","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","volume":"70","author":"M Trauner","year":"2019","unstructured":"Trauner\u00a0M, Gulamhusein\u00a0A, Hameed\u00a0B et\u00a0al (2019) The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology 70:788\u2013801","journal-title":"Hepatology"},{"key":"5722_CR52","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00277-016-2674-2","volume":"95","author":"BE Vaa","year":"2016","unstructured":"Vaa\u00a0BE, Tefferi\u00a0A, Gangat\u00a0N et\u00a0al (2016) Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. Ann Hematol 95:1185\u20131189","journal-title":"Ann Hematol"},{"key":"5722_CR53","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40257-022-00710-2","volume":"23","author":"A Vander Does","year":"2022","unstructured":"Vander Does\u00a0A, Levy\u00a0C, Yosipovitch\u00a0G (2022) Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments. Am J Clin Dermatol 23:647\u2013659","journal-title":"Am J Clin Dermatol"},{"key":"5722_CR54","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi\u00a0AM, Kiladjian\u00a0JJ, Griesshammer\u00a0M et\u00a0al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N\u00a0Engl J Med 372:426\u2013435","journal-title":"N Engl J Med"},{"key":"5722_CR55","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek\u00a0S, Mesa\u00a0RA, Gotlib\u00a0J et\u00a0al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N\u00a0Engl J Med 366:799\u2013807","journal-title":"N Engl J Med"},{"key":"5722_CR56","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2340\/00015555-3164","volume":"99","author":"E Weisshaar","year":"2019","unstructured":"Weisshaar\u00a0E, Szepietowski\u00a0JC, Dalgard\u00a0FJ et\u00a0al (2019) European S2k Guideline on Chronic Pruritus. Acta Derm Venereol 99:469\u2013506","journal-title":"Acta Derm Venereol"},{"key":"5722_CR57","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1111\/jdv.16360","volume":"34","author":"A Wieczorek","year":"2020","unstructured":"Wieczorek\u00a0A, Krajewski\u00a0P, Koziol-Galczynska\u00a0M et\u00a0al (2020) Opioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus. J\u00a0Eur Acad Dermatol Venereol 34:2368\u20132372","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5722_CR58","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1007\/s13555-025-01548-2","volume":"15","author":"F Witte","year":"2025","unstructured":"Witte\u00a0F, Weisshaar\u00a0E, Metz\u00a0M et\u00a0al (2025) Aquagenic Pruritus Questionnaire: Predicting Myeloproliferative Neoplasms in Patients with Aquagenic Pruritus. Dermatol Ther (Heidelb) 15:3593\u20133604","journal-title":"Dermatol Ther (Heidelb)"},{"key":"5722_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2025.167972","volume":"1871","author":"F Wolters","year":"2025","unstructured":"Wolters\u00a0F, Tolenaars\u00a0D, Van Weeghel\u00a0M et\u00a0al (2025) The role of bile salts in itch receptor activation. Biochim Biophys Acta Mol Basis Dis 1871:167972","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"5722_CR60","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jpainsymman.2012.01.012","volume":"45","author":"A Wright","year":"2013","unstructured":"Wright\u00a0A, Wijeratne\u00a0A, Hung\u00a0T et\u00a0al (2013) Prevalence and severity of pruritus and quality of life in patients with cutaneous T\u2011cell lymphoma. J\u00a0Pain Symptom Manage 45:114\u2013119","journal-title":"J Pain Symptom Manage"},{"key":"5722_CR61","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/hep.32599","volume":"77","author":"J Xu","year":"2023","unstructured":"Xu\u00a0J, Wang\u00a0Y, Khoshdeli\u00a0M et\u00a0al (2023) IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. Hepatology 77:20\u201332","journal-title":"Hepatology"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05722-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05722-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:04:02Z","timestamp":1783080242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05722-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5722"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05722-1","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"11 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Koschmieder hat folgende potentiellen Interessenskonfilkte angegeben: Mittel zur F\u00f6rderung von Forschungsprojekten durch Novartis und Bristol-Myers Squibb (BMS); Advisory Board-Honoare durch Incyte, Novartis, BMS und GlaxoSmithKline (GSK); Vortragshonorare durch Novartis, BMS, Incyte und GSK; weitere Unterst\u00fctzung (z.\u202fB. Kongressreisekosten) durch Novartis, BMS, Incyte und GSK. M.\u00a0Brand und A.E.\u00a0Kremer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}